IADR Abstract Archives

Foaming Gel with Cetylpridinium Chloride and Antioxidants Reduces Gingival Inflammation

Objectives: A pilot randomized-controlled clinical trial was performed to evaluate the efficacy of a dental foaming gel containing cetylpridinium chloride, hydrogen peroxide and antioxidants on periodontal/oral health.
Methods: Individuals with gingivitis or mild-moderate periodontitis (n=36) were included and randomly assigned to Group 1 and 2 using dental foaming gel loaded on a mouthpiece with heat source or on a toothbrush, respectively, in addition to regular twice-daily brushing. Group 3 served as control with twice daily brushing and further assigned split-mouth to Group 3a-un-flossed and Group 3b-flossed. Gingival index (GI) and bleeding on probing (BOP) were evaluated in addition to plaque index (PI), pocket depth and clinical attachment loss at days 14, 28, 42 (treatment) and 60 (maintenance). Subgingival plaque microbial profiles and gingival crevicular fluid (GCF) cytokine levels were determined by DNA-DNA hybridization and multiplexing assays, respectively. Exploratory analyses included esthetic outcomes: changes in tooth color and levels of volatile sulfur compounds in breath. Statistical analyses were conducted using ANOVA with a post-hoc analysis of Fisher’s LSD.
Results: Use of dental foaming gel in both groups resulted in significant changes in GI and BOP at Day-42 compared to control and un-flossed control (p<0.05). Heat-enhanced gel significantly reduced the PI in Group 1 at Day-42 compared to control and un-flossed control (p=0.02; p=0.007, respectively). GCF IL-6 and TNF-α levels were significantly reduced in Group 2 compared to control (pIL-6=0.01, pTNF-α=0.02). Dental foaming gel resulted in greater reductions in periodontopathogens, while health-associated species remained stable. Despite cessation of adjunct treatments, Group 1 and 2 continued having reduced levels of GI, BOP and PI at Day-60 (p<0.05).
Conclusions: The new dental foaming gel improves oral health by reducing gingival inflammation at the local site in addition to better esthetic outcomes.
IADR/AADR/CADR General Session
2019 IADR/AADR/CADR General Session (Vancouver, BC, Canada)
Vancouver, BC, Canada
2019
0919
  • Levine, Jonathan  ( Jonathan B. Levine & Associates , New York , New York , United States )
  • Goncalves, Jordan  ( GLO Science, Inc. , New York , New York , United States )
  • Floros, Constantinos  ( The Forsyth Institute , Cambridge , Massachusetts , United States )
  • Salazar, Elida  ( The Forsyth Institute , Cambridge , Massachusetts , United States )
  • Nguyen, Olivia  ( The Forsyth Institute , Cambridge , Massachusetts , United States )
  • Hasturk, Hatice  ( The Forsyth Institute , Cambridge , Massachusetts , United States )
  • GLO Science, Inc.
    Dr. Hasturk, Olivia Nguyen, Constantinos Floros and Elida Salazar have no conflict of interests related to this study. Dr. Jonathan Levine, Founder of GLO Science, Inc, is the inventor and has issued patents on the materials tested. Jordan Goncalves is
    Poster Session
    Novel Adjunctive Therapeutics in Oral Health
    Thursday, 06/20/2019 , 11:00AM - 12:15PM